Skip to main content
Clinical Trials/NCT05794451
NCT05794451
Recruiting
Not Applicable

Developing an Artificial Intelligence System to Detect Mild Cognitive Impairment and Alzheimer's Disease Dementia Through Self-Figure Drawing: An Innovative Approach

University of Haifa1 site in 1 country4,000 target enrollmentMarch 20, 2023

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Alzheimer Disease
Sponsor
University of Haifa
Enrollment
4000
Locations
1
Primary Endpoint
Cognition for adults diagnosed with Alzheimer's disease
Status
Recruiting
Last Updated
last year

Overview

Brief Summary

Alzheimer's disease dementia (AD) is a debilitating and prevalent neurodegenerative disease in older adults globally. Cognitive impairment, a hallmark of AD, is assessed through verbal tests that require high specialization, and while accepted as screening tools for AD, general practitioners seldom use them. AD can be diagnosed with expensive, invasive neuroimaging and blood tests, but these are usually conducted when cognitive functioning is already severely impaired. Thus, finding a novel, non-invasive tool to detect and differentiate mild cognitive impairment (MCI) and AD is a prime public health interest. Self-figure drawings (a projective tool in which individuals are asked to draw a picture of themselves), are easy to administer and have been shown to differentiate between healthy and cognitively impaired individuals, including AD. Convolutional Neural Network (CNN) (a type of deep neural network, applied to analyze visual imagery) has advanced to assess health conditions using art products. Therefore, the proposed study suggests utilizing CNN-based methods to develop and test an application tailored to differentiate between drawings of individuals with MCI, AD, and healthy controls (HC) using 4,000 self-figure drawings. This

Registry
clinicaltrials.gov
Start Date
March 20, 2023
End Date
December 31, 2025
Last Updated
last year
Study Type
Observational
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Johanna Czamanski-Cohen

Senior Lecturer

University of Haifa

Eligibility Criteria

Inclusion Criteria

  • Adults aged 60 and above with subtle signs of risk of future cognitive decline, residing in the community or in nursing homes with a minimum of 10 years of education.

Exclusion Criteria

  • Current or past psychiatric illness, the presence of congenital/organic cognitive condition, severe visual or motor impairment, and terminal illness (to avoid the effect of comorbidities).

Outcomes

Primary Outcomes

Cognition for adults diagnosed with Alzheimer's disease

Time Frame: One day

The Self-reported Cognitive Difficulties (CDS)75 is a 39-item questionnaire that requires participants or their caregivers in case of AD to rate how often they currently experience cognitive difficulties in everyday life using a 5-point scale (0 -"never" to 4 -"very often").

Cognition

Time Frame: One day

The Montreal Cognitive Assessment (MoCA) is a 10-minute paper-based test that aims to detect MCI in older patients with symptomatology, suggesting impaired cognition. The MoCA is composed of 12 tasks to detect short-term memory, visuospatial ability, executive functioning, phonemic fluency, abstraction, attention, concentration, working memory, language, and orientation.

Self-figure drawing -Cognition

Time Frame: One day

Self-figure drawing. Participants will be asked to draw themselves using a pencil on an A4-sized sheet of paper.

Study Sites (1)

Loading locations...

Similar Trials